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The anterior cruciate ligament (ACL) usually fails to heal after rupture mainly due to the inability of the cells
within the ACL tissue to establish an adequate healing process, making graft reconstruction surgery a necessity.
However, some reports have shown that there is a healing potential of ACL with primary suture repair.
Although some reports showed the existence of mesenchymal stem cell-like cells in human ACL tissues, their
origin still remains unclear. Recently, blood vessels have been reported to represent a rich supply of stem/
progenitor cells with a characteristic expression of CD34 and CD146. In this study, we attempted to validate the
hypothesis that CD34- and CD146-expressing vascular cells exist in hACL tissues, have a potential for multi-
lineage differentiation, and are recruited to the rupture site to participate in the intrinsic healing of injured ACL.
Immunohistochemistry and flow cytometry analysis of hACL tissues demonstrated that it contains significantly
more CD34 and CD146-positive cells in the ACL ruptured site compared with the noninjured midsubstance.
CD34 +CD45 - cells isolated from ACL ruptured site showed higher expansionary potentials than CD146+
CD45- and CD34-CD146-CD45- cells, and displayed higher differentiation potentials into osteogenic, adi-
pogenic, and angiogenic lineages than the other cell populations. Immunohistochemistry of fetal and adult hACL
tissues demonstrated a higher number of CD34 and CD146-positive cells in the ACL septum region compared with
the midsubstance. In conclusion, our findings suggest that the ACL septum region contains a population of
vascular-derived stem cells that may contribute to ligament regeneration and repair at the site of rupture.
Introduction
Ligaments, made of dense connective parallel tissue fi-bers, play an essential role in mediating normal move-
ment and stability of joints. Injury to these systems causes
significant joint instability, which may lead to injury of other
tissues and the development of degenerative joint disease. In
most cases, such as with anterior cruciate ligament (ACL) [1]
injury, healing fails to take place and local autograft or allo-
graft are required to replace the native ligament. Among lig-
ament injuries, the ACL is one of the most commonly injured
structures in the knee, with approximately 100,000 ACL re-
constructions performed annually in the United States alone
[2]. It is well known that the ACL consists of 2 functional
bundles, the anteromedial [1] and posterolateral [1] bundles
[3–7]. The nomenclature of these 2 bundles is according to
their insertion on the tibial footprint where the anteriormedial
(AM) bundle inserts anteromedially and the posterior lateral
(PL) bundle inserts posterolaterally. Ferretti et al. have shown
that the fetus also has a distinct ACL anatomywith 2 bundles,
with a well-defined septum, constituted of vascularized con-
nective tissue, dividing the AM and PL bundles [8].
Whereas most surgical procedures for ACL reconstruction
require healing of tendon grafts in a surgically created bone
tunnel, the attachment between the tendon and the bone is
the weakest region in the early post-transplantation period
[9,10]. In fact, it is reported that the mechanical properties of
the healing ligament have not returned to normal 1 year after
injury in both rabbit and canine models [11,12]. Therefore
secure fixation of the tendon graft to the bone is a significant
factor in allowing earlier and more aggressive rehabilitation
and earlier return to sports and work. To this end, tissue
engineering using stem/progenitor cells and/or growth
factors with biocompatible scaffolds have recently focused
on their potential for early healing and regeneration of graft
tendon–bone integration [13].
Over the last decade, there has been considerable contro-
versy about ACL intrinsic healing potential. Some surgeons
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have reported that the ACL does not heal without recon-
struction due to lack of blood clot formation, insufficient
vascular supply, deficits in intrinsic cell migration, impaired
growth factor ability, and effects of synovial fluid on cell
morphology [14,15]. On the other hand, others have re-
ported that the ACL spontaneously heals without surgery
[16–18] or only with primary sutures [19–22]. In fact, during
acute and sub-acute arthroscopic procedures for ACL re-
construction, a tibial stump is often observed and this
stump can have connecting fibers to the femur and the tibia
or between the posterior cruciate ligament [4] and tibia,
suggesting the existence of healing potential in ACL fibers.
However, there is no scientific evidence showing the heal-
ing potential in the ACL tissues. Stem cells are an attractive
cell source because of their potential for high expansion,
self-renewal, and multipotent differentiation capacities and
could potentially be a therapeutic tool for aiding in the
healing of injured ACL. Although some reports show the
existence of mesenchymal stem cell-like cells [1] in human
ACL tissues [23,24], their origin and characteristics still re-
main unclear. Recently, blood vessels have been reported to
be a richer supply of stem/progenitor cells with a charac-
teristic of expression of CD34 and CD146 surface cell
markers [25–28]. Our laboratory has also identified, with
molecular markers and purified by flow cytometry, 2
populations of cells that are developmentally and anatom-
ically related to blood vessel walls in human tissues:
myoendothelial cells, found in skeletal muscle and coex-
pressing markers of endothelial and myogenic cells (CD34
and CD56), and pericytes (positive for CD146)—also known
as mural cells—which surround endothelial cells in capil-
laries and microvessels. These populations exhibit multi-
lineage developmental potential and differentiate, in culture
and in vivo, into skeletal myofibers, bone, cartilage, and
adipocytes [28–30].
We hypothesized that CD34- and CD146-expressing vas-
cular cells exist within the ACL tissues, especially in the
septum region, and have a potential for multi-lineage dif-
ferentiation and can be recruited to the site of rupture in the
ACL to improve intrinsic healing.
Materials and Methods
Samples
Six ACLs were harvested from spontaneously or thera-
peutically aborted human fetuses that were less than 24
weeks of gestational age. The specimens were de-identified,
coded, and provided by a certified Honest Broker. Human
adult ACL ruptured tissues were harvested from subjects
undergoing arthroscopic primary ACL reconstruction
(22.5 – 3.8 years old, 5.1 – 1.9 months postinjury, n = 8). The
Institutional Review Board (IRB) protocols were approved
by the IRB at the University of Pittsburgh.
Hematoxylin–eosin staining
The excised fetal and adult ACL tissues were frozen in
2-methylebutane precooled in liquid nitrogen, and then
stored at - 80C until they were cryosectioned. Six-microm-
eter sections were prepared. Hematoxylin and eosin (H&E)
staining was performed for histomorphological evaluation
following standard protocols (n= 3).
Immunohistochemical staining
The excised fetal and adult ACL tissues (n= 3) were frozen
in 2-methylebutane precooled in liquid nitrogen, and then
stored at -80C until theywere cryosectioned. Six-micrometer-
thick sections were fixed in 4% paraformaldehyde for 5min
and incubated in 10% sheep serum in 2% triton-phosphate-
buffered saline (PBS) for 30min at room temperature. ACL
tissues were immunostained for CD34 (stem cell marker) and
CD146 (pericyte marker), coupled with a-smooth muscle
actin (a-SMA) to detect various smooth muscle cells around
the arterioles. Primary antibodies were purified mouse anti-
human CD34 (BD Pharmingen; 1:50), and mouse anti-human
CD146 (Calbiochem; 1:1,000). These were incubated for 3 h at
room temperature, followed by PBS washes and incubation
with secondary antibodies, anti-mouse Cy-3 (Sigma-Aldrich;
1:500) for 1 h at room temperature. FITC-conjugated anti-a-
SMA (Sigma; 1:500) was added for 1 h at room temperature
to detect various cells around the arterioles. Control sections
were stained without the addition of the primary antibodies.
Nuclei were stained with 4,6-diamidino-2-phenylindole
(DAPI, Sigma; 100ng/mL) for 5min at room temperature. All
sections were mounted with gel mount aqueous mounting
medium (Sigma) and slides were observed on a Nikon Eclipse
E800 (Nikon Corp.) epifluorescence microscope.
Cell isolation
The human adult ACL tissues were transported in sterile
saline solution on ice. The excised ACL tissues (n= 5) were
dissected into 2 regions, the ruptured site (Fig. 1A) and the
midsubstance site (Fig. 1B). The tissues were minced into
small pieces approximately 1 to 2mm3, washed 3 times in
PBS, and then digested with 0.4% collagenase type I (0.4%
w/v) (Invitrogen) in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS)
and 1% penicillin/streptomycin (standard medium) for 4 to
6 h. Cells were spun down, resuspended in medium, passed
through a 70-mm pore size nylon filter (BD), and washed
twice with the same medium. Isolated cells from each region
were cultured for 2–3 days in the standard DMEM.
Characterization of ACL-derived cells
Adult ACL-derived cells from each region were charac-
terized by fluorescence-activated cell sorting (FACS) for
FIG. 1. Rich vascularity in the anterior cruciate ligament
(ACL) tissue. Arthroscopic findings show the representative
ruptured site with hematoma (A) and tissue including sep-
tum divided by anteromedial and posterolateral bundles (B).
Color images available online at www.liebertonline.com/scd
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CD34 and CD146 expression. Cells were first incubated with
mouse serum (Sigma; 1:10) in FACS buffer for 10min on ice,
and then were incubated with CD146-PE, CD34-APC, and
CD45-FITC (BD Pharmingen) for 30min. To exclude dead
cells, 7-aminoactinomycin D (Via-probes; BD Pharmingen)
was added to each tube. Live cells were analyzed using a
FACS Aria Cell-Sorting System (BD) and CellQuest softwere
(BD). After examining the cell marker profiles, hematopoietic
cells (CD45-positive cells) were gated out and CD34 + ,
CD146 + , and CD34-CD146- cells were sorted following a
protocol described by Zheng and Crisan et al. [28,29] and
these 3 fractions were tested for expansion potential and
multilineage differentiation capacity including osteogenesis,
chondrogenesis, adipogenesis, and endotheliogenesis. In
addition, CD34+ , CD146 + , and CD34 -CD146 - cells were
cultured in DMEM, supplemented with 10% FBS, 10% horse
serum, 1% penicillin/streptomycin, and 0.5% chick embryo
extract for 2 weeks, and then were characterized by FACS for
CD34, CD146, CD45, CD133, CD56, CD105, CD44, CD90,
and CD73 expression. Antibodies were as follows: CD146-
PE, CD34-FITC, CD45-FITC, CD133-PE, CD105-APC, CD44-
PE, CD90-APC, CD73-PE, and CD56-APC (BD Pharmingen).
Assessment of expansion potential
To assess proliferation potential, CD34+ , CD146 + , and
CD34 -CD146 - cells (n = 5) were plated in 75-cm2 collagen-
coated flasks, and routine cell expansion was performed
every 10 days. At each passage, cells were replated to a
density of 1.0 · 105 cells/flask. The number of population
doublings (PDs) for each subculturing was calculated as the
log2 (N/N0).
Assessment of potential multilineage differentiation
Osteogenic differentiation assay. The osteogenic assay was
performed as described previously (n = 5) [31,32]. In brief,
monolayer cultures of sorted cells from ACL tissues were
treated with standard medium supplemented with dexa-
methasone (0.1mM) (Sigma), ascorbate-2-phosphate (50mM)
(Sigma), b-glycerophosphate (10mM) (Sigma), and bone
morphogenetic protein (BMP) 4 (100 ng/mL) (Sigma) and
were incubated at 37C in 5% CO2 for 7 days. To assess the
ability to undergo osteogenesis, cells (1.0 · 105) were cultured
in 6-well plates in osteogenic medium. The medium was
changed every 3 days. Osteogenesis was assessed using ALP
staining at day 7. Cells (2.5 · 105) were also placed in 15mL
conical polypropylene tubes and were centrifuged at 600 g
for 5min to establish the pellet culture assays. Pellets were
cultured for 21 days in the osteogenic medium and were
evaluated for their bone volume using a micro-CT (SCANCO
Medical). After scanning, pellets were embedded in paraffin,
sectioned, and stained with von Kossa solution for the as-
sessment of mineralization. Total RNA was harvest on day
21 from the cells in monolayer culture with osteogenic me-
dium. Expression of osteogenic genes collagen type IA2
(COL I) and osteocalcin was analyzed by reverse transcrip-
tion–polymerase chain reaction (RT-PCR).
Chondrogenic differentiation assay
To assess the ability of the ACL-derived cells to undergo
chondrogenesis, pellet cultures were established as described
previously (n= 5) [33–35]. Sorted cells (2.5 · 105) were placed
in 15mL conical polypropylene tubes and were centrifuged
at 600 g for 5min, and then were left on the bottom of the
tube and cultured in chondrogenic medium (Lonza) sup-
plemented with transforming growth factor b3 (TGF-b3)
[10 ng/mL] (R&D System). After the addition of 500 mL of
chondrogenic medium to each tube, the pellets were incu-
bated at 37C in 5% CO2. The medium was changed every
3 days. Pellets were harvested at day 14 and their sizes
were measured using ImageJ software (NIH). Paraffin-
embedded pellets were assessed for chondrogenesis by Al-
cian blue staining at a low pH to stain the highly sulfated
proteoglycans that are characteristic of cartilaginous matrix,
and were counterstained with nuclear fast red, which stains
cell nuclei. Total RNA was harvested from other pellets on
day 21 for RT-PCR analysis. Expression of chondrogenic
genes collagen type IIA2 (COL II) and aggrecan were ana-
lyzed by RT-PCR.
Adipogenic differentiation assay
The in vitro adipogenic assay was performed as described
previously (n= 5) [31,32]. Cells (1.0 · 105 per well) were cul-
tured in 6-well plates for 14 days in adipogenic medium:
standard medium supplemented with insulin (10mM),
dexamethasone (1 mM) (Sigma), isobutyl-methylxanthine
(0.5mM) (Sigma), and indomethacin (200 mM) (Sigma), and
had the medium changed every 2 days. Adipogenesis was
assessed using Oil Red O stain, which serves as an indicator
of intracellular lipid accumulation. The cells were fixed
for 10min at room temperature in 10% neutral buffered
formalin and then washed with PBS. They were then incu-
bated in Oil Red O reagent for 30min and washed with 60%
isopropanol 1 time and with PBS 2 times. Total RNA was
harvested for RT-PCR on day 14 from the cells in monolayer
culture-maintained adipogenic medium. Expression of adi-
pogenic genes peroxisome proliferator-activated receptor
gamma (PPARc) and lipoprotein lipase (LPL) was analyzed
by RT-PCR.
Endothelial differentiation assay
The in vitro endothelial differentiation assay was per-
formed as described previously (n = 5) [36–39]. Cells (5.0 · 103
per well) were cultured on 24-well plates with endothe-
lial growth medium-2 (EGM-2) Bullet kit (endothelial cell
basic medium, hydrocortisone, FGF-B, vascular endothelial
growth factor (VEGF), R3-IGF-1, ascorbic acid, EGF, GA-1000,
and heparin) supplemented with 10% FBS and incubated at
37C in 5% CO2 for 1 week. For demonstrating cellular ability
to uptake 1,1¢-dioctadecyl-3,3,3¢,3¢-tetramethylindocarbocy-
anine (DiI)-labeled acetylated low-density lipoprotein (acLDL)
(Biomedical Technologies) and bind to Ulex europeus lectin
(Molecular Probes), the cells were first incubated with DiI-
acLDL (10mg/mL) at 37C for 4h and then fixed with 1%
paraformaldehyde for 10min. After washes, the cells were
continuously incubated with FITC–Ulex europeus lextin
(10mg/mL) for 1h. Then, the slides were mounted by DAPI
mounting medium and viewed using an inverted fluorescence
microscope.
The formation of endothelial tubular structures was also
studied in vitro in Matrigel cultures. Briefly, cells (1.5 · 104)
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in endothelial basal medium-2 (EBM-2) were seeded onto
48-well plates coated with Matrigel (BD Biosciences). The
cells were cultured at 37C for 24 h and observed with a
microscope. The total tube length was calculated from 10
randomly selected low-power fields for each experiment.
Total RNA was harvested for RT-PCR on day 7 from
the cells in monolayer culture-maintained endothelial cell
culture EGM-2. Expression of endothelial cell genes VE-
cadherin (VE-cad) and CD31 was analyzed by RT-PCR.
RNA isolation and RT-PCR
Total RNA was extracted from these cells or pellets using
RNeasy plus Mini Kit (Qiagen) in accordance with the
manufacture’s instruction. One microgram of total RNA was
used for random hexamer-primed cDNA synthesis using RT
of the SuperScript II preamplification system (Invitrogen).
Equal amounts of cDNA synthesis were used as templates
for RT-PCR amplification per 25 mL reaction volume using
Taq DNA polymerase (Invitrogen) and 50pmol of gene-
specific primers. The sequences and product sizes of primers
for COL I, osteocalcin, COL II, aggrecan, PPARg, LPL, VE-
cad, CD31, and b-actin are listed in Table 1. RT-PCR am-
plifications were performed by preheating of the mixture
at 95C for 5min followed by 35 cycles of 1 s at 95C, 45 s at
58C, and 1 s at 72C. A final extension of 10min was per-
formed at 72C. The PCR products were resolved by elec-
trophoresis on 1.5% agarose gels and observed by ethidium
bromide staining. mRNA expression of b-actin was used to
normalize gene expression. Total RNA extracted from fetal
cartilage, bone, fat tissues, and human umbilical vein endo-
thelial cells was used for positive control of chondrogenic,
osteogenic, adipogenic, and endotheliogenic gene expression.
Statistical analysis
The comparisons among 3 populations were made using
the one-way analysis of variance. Post hoc analysis was
performed by Fisher’s protected least significant difference
(PLSD) test. A probability value of < 0.05 was considered to
denote statistical significance.
Results
Vascular cells of fetal ACL
In fetal ACL tissue, there clearly exists the septum that
divides the AM and PL bundles (Fig. 2A), as previously
described [8]. CD34 and CD146-positive cells (red) can be
seen surrounding a-SMA (green)-positive arterioles in the
septum region (Fig. 2B, C). On the other hand, in the mid-
substance, CD34 and CD146-positive cells were found in the
region without a-SMA-positive arterioles (Fig. 2B, C).
H&E and SMA staining
H&E staining of adult ACL tissues demonstrated more
blood vessel-like formation in the ruptured and septum re-
gions than in the midsubstance region (Fig. 3A). These
structures were confirmed as blood vessels by SMA staining
(Fig. 3B). The number of SMA-positive cells was significantly
greater in the rupture and septum regions than the mid-
substance region (rupture, 205.7– 26.6; septum, 234.7– 42.8;
midsubstance, 93.7 – 27.2/mm2, respectively; P < 0.05 for
rupture or septum vs. midsubstance region) (Fig. 3C).
Immunohistochemical staining and flow
cytometry analysis
CD34-positive cells (red) located in a-SMA-positive arte-
rioles (green) were abundantly found in the ruptured and
septum regions compared with the midsubstance region (Fig.
3D). CD146-positive cells (red) located surrounding a-SMA
(green)-positive arterioles were also found in the ruptured and
septum regions compared with the midsubstance region (Fig.
3E). In the characterization of the adult ACL-derived cells by
FACS analysis, the percentage of cells positive for CD34 were
46.4–2.8 at the rupture site and 8.6%–0.7% in the mid-
substance region, and of the number of cells positive for CD146
Table 1. Primer Sequences and Product Sizes for Reverse Transcription–Polymerase Chain Reaction Analysis
Gene 5¢ DNA sequence 3¢ Product size (bp)
Collagen I Forward TGACGAGACCAAGAACTG 539
Reverse CCATCCAAACCACTGAAACC
Osteocalcin Forward GTGCAGAGTCCAGCAAAGGT 300
Reverse GCAAGGGGAAGAGGAAAGAA
Collagen II Forward GGCTCCCAGAACATCACCTA 198
Reverse ATCCTTCAGGGCAGTGTACG
Aggrecan Forward TGAGTCCTCAAGCCTCCTGT 445
Reverse GTGCCAGATCATCACCACAC
PPARg Forward AAGACCACTCCCACTCCTTTG 554
Reverse TGACGAGACCAAGAACTG
LPL Forward GGGCATGTTGACATTTACCC 461
Reverse GGCAGAGTGAATGGGATGTT
VE-cadherin Forward ACGCCTCTG TCATGTACCAAA TCCT 461
Reverse GGCCTCGACGATGAAGCTGTATT
CD31 Forward ATCGATCAGTGGAACTTTGCCTATT 363
Reverse GTG GCA TTT GAG ATT TGA TAG A
B-actin Forward CCTCGCCTTTGCCGATCC 225
Reverse GGAATCCTTCTGACCCATGC
LPL, lipoprotein lipase; PPARg, peroxisome proliferator-activated receptor gamma.
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were 7.3–2.5 at the rupture site and 1.7%–0.7% in the mid-
substance region. The number of CD34+ and CD146+ cells
was significantly higher at the rupture site when compared
with the midsubstance region (Fig. 3F, G).
Expansion potential of adult ACL-derived cells
Adult ACL-derived cells from each region were sorted for
expression of CD34 and CD146 after gating out the hemato-
poietic (CD45-positive cells) cells (Fig. 4A). After sorting,
6 populations (CD34+CD45- , CD146+CD45- , CD34-
CD146-CD45- cells from the rupture site and midsubstance
region) were cultured for 2 weeks (n=3 in each group). Cells
from the midsubstance region did not expand well; therefore,
only cells from the rupture site were analyzed for cell char-
acterization. Interestingly, the CD34+CD45- cell fraction lost
their CD34 expression and expressed CD146, CD105, CD44,
CD90, and CD73 (Fig. 4B). In addition, all these cell popula-
tions showed similar patterns of cell surface marker positivity
for CD146, CD105, CD44, CD90, and CD73 expression and
negativity for CD45, CD133, CD56, and CD34 (Table 2) (Fig.
4C). Analysis of short-term kinetics showed that all popula-
tions had similar PD times until 3 passages; however, after
moderate expansion over 4 passages, CD34+CD45- cells
exhibited significantly higher PD times than the other groups
in all passages (P< 0.01 for CD34+ vs. CD146+ , CD146+ vs.
CD34-CD146- in passage 4–10) (Fig. 4D).
Multilineage differentiation of adult ACL cells
Osteogenic differentiation. In monolayer cultures all the
population showed positive ALP staining; however, the CD34+
cells revealed a larger number of positive cells than the CD146+
cells and CD34-CD146- cells (Fig. 5A). von Kossa staining
showed a greater number of positive cells in the CD34+ cell
group than the other populations (Fig. 5B). Micro CT analysis
showed greater mineralization in the CD34+ cell group com-
pared with the other populations (Fig. 5C). Moreover, bone
volume and density of pellets in the CD34+ cell group were
significantly larger than the other populations (bone volume:
CD34+ , 0.84–0.03; CD146, 0.43–0.01, CD34-CD146- ,
0.24–0.01mm3, bone density: CD34+ , 288.6–21.3; CD146,
243.9–9.7, CD34-CD146- , 180.9–11.5mg HA/ccm) (Fig. 5D).
mRNA expression of COL I and osteocalcin was detected from
pellets in all populations (Fig. 5E); however, the expression ratio
of COL I to b-actin was significantly greater in the CD34+and
CD146+ cell populations than in the CD34-CD146- cell
population (CD34+ , 0.758–0.003; CD146+ , 0.737–0.061;
CD34-CD146- , 0.380–0.022; respectively. P<0.01 for CD34+
vs. CD34-CD146- , P<0.05 for CD146+ vs. CD34-CD146- )
(Fig. 5F). The expression ratio of osteocalcin to b-actin was sig-
nificantly greater in the CD34+ cell population than in the
CD34-CD146- cell population (CD34+ , 0.777–0.067;
CD146+ , 0.649–0.007; CD34-CD146- , 0.416–0.046; respec-
tively. P<0.05 for CD34+ vs. CD34-CD146- ) (Fig. 5F).
FIG. 2. Vascular cells of fetal ACL.
In fetal ACL tissue, there clearly ex-
ists the septum dividing the anterior
medial (AM) and PL bundles (A)
(· 100). CD34 and CD146-positive cells
(red) were located surrounding a-
smooth muscle actin (a-SMA) (green)-
positive arterioles in the septum region
(B, C). In the midsubstance, CD34 and
CD146-positive cells were found in the
region without a-SMA-positive arteri-
oles (B, C). Scale bar: 50mm. Color images
available online at www.liebertonline
.com/scd
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Chondrogenic differentiation
All the populations formed pellets and their diameters
were 0.72 – 0.02, 0.79 – 0.02, and 0.84 – 0.05 (mm) for the
CD34+ , CD146+ , and CD34 -CD146 - cells, respectively,
with the CD34-CD146- cells generating significantly larger
pellets than the other populations (Fig. 6A, B). Pellets gen-
erated by the CD34-CD146 - cells also stained very well
with Alcian blue compared with the other populations (Fig.
6C). mRNA expression of COL II and aggrecan was detected
in pellets from all the populations (Fig. 6D). There were
no significant differences in the expression ratio of COL II to
b-actin and aggrecan to b-actin among any of the cell popu-
lations (COL II; CD34+ , 0.885– 0.019; CD146+ , 0.931– 0.034;
FIG. 3. (A) H&E staining
showed more vascular-like
structures in the septum and
ruptured site compared with
the midsubstance. Arrow:
vascular-like structure. Scale
bar: 50 mm. (B) a-SMA stain-
ing recognized these struc-
tures as blood vessels. Scale
bar: 50 mm. (C) The number of
a-SMA-positive cells was
significantly greater in the
ruptured and septum regions
than the midsubstance re-
gion. *P < 0.05. (D) CD34-
positive cells (red) located in
a-SMA-positive arterioles
(green) were abundantly
found in the ruptured and
septum regions compared
with the midsubstance re-
gion. (E) CD146-positive cells
(red) located surrounding
a-SMA (green)-positive arteri-
oles were also abundantly
found in the ruptured and
septum regions compared
with the midsubstance re-
gion. (F, G) Fluorescence-
activated cell sorting analysis
demonstrated significantly
higher numbers of CD34 + (F)
and CD146+ (G) cells at the
ruptured site compared with
the midsubstance region.
**P < 0.01. The insets in figure
A indicate the lesion shown
in Figure B. Color images
available online at www
.liebertonline.com/scd
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CD34 -CD146 - , 0.574– 0.014. P=NS. Aggrecan; CD34 + ,
1.055 – 0.052; CD146 + , 1.094 – 0.010; CD34 -CD146 - ,
1.136 – 0.068. P =NS) (Fig. 6E).
Adipogenic differentiation
All populations were stained positively for Oil Red O (Fig.
7A). The number of Oil Red O-positive cells in CD34 + ,
CD146+ , and CD34-CD146- cells were 906.7– 33.4,
816.0– 36.5, and 407.1– 34.6/mm2, respectively. Oil Red O
staining demonstrated that CD34 + cells had significantly
more adipose cells (lipid droplets) compared with the other
populations (P < 0.01 for CD34+ and CD146+ vs. CD34 -
CD146- ) (Fig. 7B). mRNA expression of PPARg and LPL
was detected in all the populations (Fig. 7C). There were no
significant differences, in the expression ratio of PPARg to
FIG. 4. (A) ACL-derived
cells from the site of ACL
rupture and mid-substance
region were sorted for ex-
pression of CD34 and CD146
after gating out hematopoi-
etic (CD45-positive) cells. (B)
CD34+CD45- cell fraction
lost their CD34 expression
and showed positive expres-
sion for CD105, CD44, CD90,
and CD73 after 2 weeks of
expansion. (C) All these cell
populations showed positive
expression for CD105, CD44,
CD90, and CD73 and nega-
tive expression for CD45,
CD133, CD56, and CD34. (D)
Aftermoderate expansion over
4 passages, CD34+CD45-
cells exhibited significantly
higher population doublings
than the other groups in all
passages. **P<0.05 for CD34+
versus CD146+ and CD34-
CD146- , *P<0.05 forCD146+
versus CD34-CD146- .
Table 2. Phenotypic Characterization of Anterior Cruciate Ligament-Derived Cells
by Fluorescence-Activated Cell Sorting Analysis
(%, mean – SE)
CD 146 CD 105 CD 44 CD 90 CD 73 CD 45 CD 133 CD 56 CD 34
CD 34+ 45.1 – 2.7 89.9 – 1.2 92.9 – 0.9 98.0 – 0.7 92.1 – 0.8 3.9 – 2.0 5.9 – 2.8 2.6 – 0.4 8.3 – 1.3
CD 146 + 82.2 – 1.5 91.3 – 0.8 60.6 – 2.6 68.7 – 2.2 66.5 – 1.9 9.2 – 3.4 16.3 – 3.4 15.3 – 1.7 4.0 – 2.3
CD34 -CD146 - 30.7 – 2.9 88.1 – 1.1 90.9 – 0.3 96.6 – 0.6 85.2 – 0.8 0.9 – 0.6 2.2 – 1.0 0.8 – 0.5 1.3 – 0.6
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FIG. 5. (A) In monolayer culture, all population showed positive ALP staining; however, CD34+ cells revealed a larger
number of ALP-positive cells than CD146+ cells and CD34 -CD146 - cells. Scale bar: 200 mm. (B) Mineralized nodular
structures observed by von Kossa staining showed a greater number of positive cells in the CD34 + cell population than
the other populations. Arrow: von Kossa positive. Scale bar: 200 mm. (C) Micro-CT analysis showed greater mineralization in
the CD34+ cell population compared with the other populations. Scale bar: 500mm. (D) Bone volume and density of CD34+
cells pellets were significantly larger than the other populations. **P < 0.01, *P < 0.05. (E) The mRNA expressions of collagen
type IA2 (COL I) and osteocalcin were detected from pellets in all populations. (F) mRNA expression of COL I and
osteocalcin was detected from pellets in all cell populations. The expression ratio of COL I to b-actin was significantly greater
in the CD34+ and CD146+ cell populations than in the CD34-CD146- cell population. The expression ratio of osteocalcin
to b-actin was significantly greater in the CD34+ cell population than in the CD34 -CD146 - cell population. **P < 0.01,
*P < 0.05. Color images available online at www.liebertonline.com/scd
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b-actin, between any of the cell populations (CD34 + ,
1.204 – 0.059; CD146 + , 1.120 – 0.066; CD34 -CD146 - ,
1.070 – 0.046. P =NS) (Fig. 7D). The expression ratio of LPL to
b-actin was significantly greater in the CD34+ and CD146+
cell populations than in the CD34-CD146- cell population
(CD34 + , 1.257– 0.068; CD146 + , 1.155– 0.035; CD34-
CD146 - , 0.957– 0.019; respectively. P < 0.05 for CD34+ and
CD146 + vs. CD34 -CD146 - ) (Fig. 7D).
Endothelial differentiation
The abilities to uptake acLDL and bind to Ulex europeus
lectin are characteristics of endothelial cells and endothelial
progenitor cells (EPCs). All populations showed double-
positive stainings for acLDL uptake and binding of Ulex
europeus lectin (Fig. 8A). All populations also showed vas-
cular tube-like structures (Fig. 8B). The tube length in
CD34 + , CD146 + , and CD34 -CD146 - cells were 6.4 – 0.6,
3.9 – 0.9, and 1.2 – 0.3/field, respectively. The tube formation
assay demonstrated that CD34+ cells showed significantly
higher potential for endothelial differentiation compared
with the other populations (Fig. 8C). mRNA expression of
CD31 and VE-cad was detected from all populations (Fig.
8D). There were no significant differences in the expression
ratio of VE-cad to b-actin among all the cell populations
(CD34+ , 1.033– 0.008; CD146+ , 0.956– 0.055; CD34-
CD146- , 0.989– 0.029. P =NS) (Fig. 8E). The expression ratio
of CD31 to b-actin was significantly greater in the CD34+
and CD146 + cell populations compared with the CD34-
CD146- cell population (CD34+ , 0.876– 0.071; CD146+ ,
0.873– 0.065; CD34-CD146 - , 0.549– 0.023; respectively.
P < 0.05 for CD34+ and CD146+ vs. CD34-CD146 - )
(Fig. 8E).
As control groups, we performed the each differentiation
assay with each cell population: CD34 + , CD146 + , and
CD34-CD146- with each differentiation medium not in-
cluding any chemical inducers. In all results of these exper-
iments, we could see no proof about the differentiations into
all lineages, including osteogenesis, adipogenesis, chon-
drogenesis, and endothelial lineage in using all cell popula-
tions (data not shown).
Discussion
Initially, our study compared the characteristics of the cell
populations isolated from the septum and midsubstance re-
gions of fetal and adult ACLs. We have found that CD34 and
CD146-positive cells were more prevalent in the septum re-
gion of the fetal and adult ACLs. When comparing immu-
nohistochemical staining results of the septum region
FIG. 6. (A, B) Although all cell
populations formed pellets,
CD34-CD146- cells showed sig-
nificantly larger sizes than the
other populations. (C) Pellets of
CD34-CD146- cells appeared to
be stained well with Alcian blue
compared with the other popula-
tions. (D) mRNA expression of
COL II and aggrecan was detected
from pellets in all populations. (E)
There were no significant differ-
ences in the expression ratio of
COL II to b-actin and aggrecan to
b-actin among all cell populations.
*P < 0.05. Color images available
online at www.liebertonline.com/
scd
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between fetal and adult ACLs, we found a thinner capillary in
the adult verses fetal septum region of the ACL. Further, the
capillaries in the fetal ACL midsubstance region did not show
positive a-SMA immunostaining, which might be explained
by their immature stage of development. A previous embry-
ologic study has indicated that the ACL begins to organize at
the gestational age of 8 weeks and is well developed by the
ninth week [40]. Gardner and O’Rahilly suggested that after
embryonic developmental stage 21, the eighth week of ges-
tational age, the ACL will continue to grow; however, no
major organizational or compositional changes will occur after
this point [41]. Ferretti et al. found that the vascularity of the
fetal ACL was abundant, with arteries and arterioles seen
during both gross and histological examination [8]. Scapinelli
et al. described the neonate middle genicular artery as having
a relatively greater caliber than is seen in adults and also has a
longer intra-articular course [42]. Although these studies have
shown the presence of an abundant vascularity in the fetal
ACL, to our knowledge, no other study has characterized
these vascular cells with immunohistochemistry as we have
done in the current study.
As CD34-positive and CD146-positive cells were more
prevalent in the septum region, the present study also com-
pared the characteristics of the cell populations isolated from
the rupture sites of an injured ACLs and the midsubstance
regions of adult ACLs. CD34-positive and CD146-positive
cells exhibited multilineage differentiation potential, includ-
ing the capacity to undergo chondrogenesis, osteogenesis,
adipogenesis, and endotheliogenesis. These findings suggest
that these cell populations exhibit vascular stem cell charac-
teristics and could contribute to primary ligament healing or
tendon–bone healing after ACL reconstruction.
Our laboratory has provided evidence that the existence of
myogenic cells is related to the endothelial cell lineage in
human skeletal muscle, confirming that endothelial and
satellite cells are closely related [29]. Covas et al. have re-
cently shown that mesenchymal stem cells (MSCs) and
pericytes are similar cell types located in the walls of the
circulatory system’s vasculature and function as cell sources
for tissue repair and maintenance [28,43]. Reports have
shown that CD34+ cells are committed not only to an en-
dothelial cell lineage but also to mural perivascular cells
FIG. 7. (A) Although all
populations were positively
stained for Oil Red O. (B) The
number of Oil Red O-positive
cells demonstrated that the
CD34+ cells showed signifi-
cantly more adipose cells
(lipid droplets) compared
with the other populations.
Scale bar: 100 mm. (C) mRNA
expression of peroxisome
proliferator-activated receptor
gamma (PPARg) and lipo-
protein lipase (LPL) was de-
tected in all populations. (D)
There were no significant dif-
ferences in the expression ra-
tio of PPARg to b-actin among
all cell populations. The ex-
pression ratio of LPL to b-
actin was significantly greater
in the CD34+ and CD146+
cell populations than in the
CD34-CD146- cell popula-
tion. **P< 0.01, *P< 0.05.
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(ie, pericytes and smooth muscle cells) [44,45]. Similarly,
vascular pericytes with CD146 expression have been sug-
gested to arise from CD34+ cells [26]. In addition to these
reports, Zengin et al. have recently reported the existence of
EPCs and stem cells in a distinct zone between the smooth
muscle and the adventitial layer of the human adult vascular
wall, which are capable of differentiating into mature en-
dothelial cells and hematopoietic and local immune cells,
such as macrophages [27]. Considering these previous re-
ports, it was hypothesized that CD34 + cells could be iso-
lated from the ACL at the site of rupture, which may have
similar characteristics to the MSCs described over the last
decade [46] and could possibly provide an attractive cell
source for tissue repair and regeneration. When cultured, the
CD34 + cells lost their expression of CD34 and expressed
several makers of MSCs, including CD146, CD44, CD90, and
CD73, and they rapidly proliferated (dramatically increased
PD times) and were found to be multipotent.
Using H&E staining and immunohistochemical a-SMA
staining, we confirmed that the septum region of the ACL
and the rupture sites of injured ACLs were richly vascular-
ized when compared with the midsubstance region. Using
immunohistochemistry and flow cytometry analysis, we
confirmed that CD34 + and CD146 + cells, which demon-
strated multilineage differentiation potential, are recruited to
the site of rupture and that there are significantly more of
these cell types in this area when compared with the mid-
substance region. These findings suggest that the rupture site
has a rich supply of vascular stem cells that could assist in
the intrinsic healing of the ACL. In 48 cases of ruptured ACL
healing patterns that were observed by Crain et al., they
reported that ruptured ACL remnants were adhering to the
FIG. 8. (A) All populations
showed double-positive
staining for acetylated low-
density lipoprotein uptake
and binding of Ulex europeus
lectin. Scale bar: 100 mm. (B)
All populations also showed
vascular tube-like structures.
Scale bar: 500mm. (C) As-
sessment of tube length
demonstrated that CD34 +
cells showed a significantly
higher potential for endothe-
lial differentiation compared
with the other populations.
(D) mRNA expression of
CD31 and VE-cadherin (VE-
cad) was detected in all pop-
ulations. (E) There were no
significant differences in the
expression ratio of VE-cad
to b-actin among all cell
populations. The expression
ratio of CD31 to b-actin was
significantly greater in the
CD34+ and CD146+ cell
populations than in the
CD34-CD146- cell popula-
tion. **P < 0.01, *P < 0.05. Col-
or images available online at
www.liebertonline.com/scd
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PCL in 38% of the cases, the roof of the notch in 8% of the
cases, and the lateral wall of the notch or medial aspect of the
lateral femoral condyle in 12% of the cases [47]. These healing
patterns could be caused by the instability of the ACL at the
rupture site in the synovial fluid, which indicates that apply-
ing appropriate primary sutures in the acute phase after injury
may be an ideal therapeutic strategy. Based on these latter
findings, it is reasonable to posit that there is a rich population
of vascular-derived cells present at the ACL rupture site,
which could relate to the reason why these reports show
spontaneous ACL healing with primary sutures [19–22].
However, the primary suture technique for repairing the
ACL tissues may be limited to acute or sub-acute cases be-
cause of the ligaments shortening and shrinking during un-
stable conditions in the synovial fluid. Therefore, recent
advances in tissue engineering suggest that suture repair and
healing of the ACL may be feasible if a biologic boost is
provided at the ligamentous gap using a tissue-engineered
scaffold. Murray et al. reported the usefulness of implanting
collagen-platelet rich plasma scaffolds for histological and
biomechanical ACL healing without reconstruction in animal
models [15,48,49]. They used collagen-platelet hydrogels to
stimulate healing in a central defect model of canine ACL
injury and a complete transection model of a porcine ACL,
resulting in significant improvements in histological and
biomechanical healing compared with the controls. From the
view point of our study, as they reported, scaffolds may be
beneficial and necessary for fixation of the ligament and re-
cruitment of cells to heal a complete rupture of the ACL.
Our study may also provide therapeutic options for
tendon–bone healing in the ACL reconstruction of the knee.
The tissues or cells from the rupture site could be valuable
when performing autografts or allografts of the ligament.
Similarly, there are some reports showing ACL cells with
MSC-like characteristics [23,24]; however, compared with
these reports the current study focused on novel vascular cell
populations that express the markers CD34 and CD146,
which demonstrated a propensity for multilineage differen-
tiation and the potential to be highly expanded. In addition,
our findings revealed that tissues at the ACL rupture site,
where vascularity is rich, possess an abundant number of
stem cells when compared with the mid-substance region of
the ligament. On the other hand, reports have shown the
contribution and therapeutic potential of MSCs for ligament
healing or tendon–bone repair [1,50–52]. Lim and Soon et al.
performed bilateral ACL reconstruction in an animal model
using grafts coated with MSCs suspended in fibrin glue
[50,51]. MSC-treated grafts showed more type II collagen
staining at the tendon–bone interface and higher biomechan-
ical strength when compared with fibrin glue-coated grafts with
MSCs. Compared with bone marrow MSCs, the ACL cells can
be derived from the rupture site of the injured ACL and have
the advantage of being easily harvested during arthroscopic
examination, which can be performed at the same time as the
primary surgery without performing any additional invasive
procedures. To confirm the potential therapeutic efficacy of
utilizing ruptured tissues or cells for tendon–bone healing,
further investigation using an in vivo animal model is required.
Especially important for ligament healing and tendon–
bone repair would be for the cells to have the ability to dif-
ferentiate into osteogenic and endothelial cell lineages. As
proof of principle in our study we demonstrated that the
vascular stem cells in the ruptured ACL tissue can differen-
tiate into osteoblasts and endothelial cells and also had the
ability to differentiate into chondrogenic and adipogenic
lineages. There are some reports concerning osteogenesis and
angiogenesis/vasculogenesis for ligament and tendon–bone
healing. To accelerate osteogenesis and/or angiogenesis for
tendon–bone healing, VEGF, granulocyte colony-stimulating
factor (G-CSF), TGF-b, BMP2, and BMP7 have recently re-
ceived attention for their therapeutic potentials (BMP2), and
BMP7 have recently received attention for their therapeutic
potential [53–57]. On the other hand, Tei et al. reported that
human G-CSF mobilized peripheral blood CD34 + cells,
which could contribute to ligament healing via their endo-
thelial differentiation (vasculogenesis) capacity and an en-
hancement of intrinsic angiogenesis by VEGF secretion, in an
immunodeficient rat model [58]. In addition, their group also
showed that peripheral blood CD34+ cells could differenti-
ate into osteoblasts as well as endothelial cells in a fracture
model [59,60]. Compared with their study, the ACL ruptured
tissue was shown to contain higher percentages of CD34+
cells (46%) than the peripheral blood (1%) [59], suggesting
that the ruptured ACL could be a richer CD34 + cell source
than the peripheral blood.
In the current study, there are some limitations. Only
relatively acute samples ranging from 3 to 8 weeks post-
injury were investigated. Similarly, we selected only young
patients from 17 to 29 years old for this study and future
studies should compare differential cellular characteristics,
including differences in gender, age, and time postinjury. In
addition, our study lacked in vivo animal studies, which are
important for demonstrating the efficacy of using these cells
to actually aid in the repair of ACL injuries.
In conclusion, our results demonstrated that ACL-derived
CD34+ cells isolated at the site of ACL rupture, which may
originate from the septum, exhibited stem cell characteristics
and may contribute to ligament or tendon–bone healing and
regeneration. The present findings provide potentially impor-
tant clinical insights for novel regenerative clinical therapies
aimed at enhancing ACL repair and regeneration after injury.
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